Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rescinnamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 0.81 |
| ▸ | HBB | P68871 | 5/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.81 |
| ▸ | CASP1 | P29466 | 4/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rescinnamine SCHEMBL15592450 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL181966 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL29365500 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL14379420 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL8261530 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL24164175 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL30401771 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| Rescinnamine SCHEMBL9382396 | 0.96 | MEN1 (0.93) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL13130009 | 0.95 | MEN1 (0.91) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL13130010 | 0.94 | MEN1 (0.89) | MEN1KMT2AKDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110494568-B | Continuous glucose monitoring using FAD-dependent glucose dehydrogenase | 龟甲万株式会社 | 2024-03-19 | — | — | CN | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4175636-A2 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | SLC18A2 916/4885MEN1 4843/4885KMT2A 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.